Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 39 entries
Sorted by: Best Match Show Resources per page
Repackaging.

Prescrire international

[No authors listed]
PMID: 26942252
Prescrire Int. 2016 Jan;25(167):10.

No abstract available.

Cite
Repackaging. Prescrire Int. 2016;25(167):10
(2016). Repackaging. Prescrire international, 25(167), 10.
"Repackaging." Prescrire international vol. 25,167 (2016): 10.
Repackaging. Prescrire Int. 2016 Jan;25(167):10. PMID: 26942252.
Copy Download .nbib Format: NLM
Global health challenges in the pharmaceutical world.

Health economics, policy, and law

Abraham J.
PMID: 19099620
Health Econ Policy Law. 2009 Jan;4:115-27. doi: 10.1017/S174413310800457X.

No abstract available.

Cite
Abraham J. Global health challenges in the pharmaceutical world. Health Econ Policy Law. 2009;4:115-27doi: 10.1017/S174413310800457X.
Abraham, J. (2009). Global health challenges in the pharmaceutical world. Health economics, policy, and law, 4115-27. https://doi.org/10.1017/S174413310800457X
Abraham, John. "Global health challenges in the pharmaceutical world." Health economics, policy, and law vol. 4 (2009): 115-27. doi: https://doi.org/10.1017/S174413310800457X
Abraham J. Global health challenges in the pharmaceutical world. Health Econ Policy Law. 2009 Jan;4:115-27. doi: 10.1017/S174413310800457X. PMID: 19099620.
Copy Download .nbib Format: NLM
Experts get snagged on health's thorniest issue.

The Health service journal

Crump H.
PMID: 18810837
Health Serv J. 2008 Sep 04;12-3.

No abstract available.

Cite
Crump H. Experts get snagged on health's thorniest issue. Health Serv J. 2008;12-3
Crump, H. (2008). Experts get snagged on health's thorniest issue. The Health service journal, 12-3.
Crump, Helen. "Experts get snagged on health's thorniest issue." The Health service journal vol. (2008): 12-3.
Crump H. Experts get snagged on health's thorniest issue. Health Serv J. 2008 Sep 04;12-3. PMID: 18810837.
Copy Download .nbib Format: NLM
Taking medications as prescribed: programs that help.

NCSL legisbrief

Cauchi R.
PMID: 20556906
NCSL Legisbrief. 2010 Jun-Jul;18(29):1-2.

No abstract available.

Cite
Cauchi R. Taking medications as prescribed: programs that help. NCSL Legisbrief. 2010;18(29):1-2
Cauchi, R. (2010). Taking medications as prescribed: programs that help. NCSL legisbrief, 18(29), 1-2.
Cauchi, Richard. "Taking medications as prescribed: programs that help." NCSL legisbrief vol. 18,29 (2010): 1-2.
Cauchi R. Taking medications as prescribed: programs that help. NCSL Legisbrief. 2010 Jun-Jul;18(29):1-2. PMID: 20556906.
Copy Download .nbib Format: NLM
Nasty side-effects anticipated.

The Health service journal

Edwards N.
PMID: 21688425
Health Serv J. 2011 Feb 24;121(6245):16-7.

No abstract available.

Cite
Edwards N. Nasty side-effects anticipated. Health Serv J. 2011;121(6245):16-7
Edwards, N. (2011). Nasty side-effects anticipated. The Health service journal, 121(6245), 16-7.
Edwards, Nigel. "Nasty side-effects anticipated." The Health service journal vol. 121,6245 (2011): 16-7.
Edwards N. Nasty side-effects anticipated. Health Serv J. 2011 Feb 24;121(6245):16-7. PMID: 21688425.
Copy Download .nbib Format: NLM
The pros and cons of essential medicines for rich countries.

BMJ (Clinical research ed.)

Reidenberg MM, Walley T.
PMID: 15539677
BMJ. 2004 Nov 13;329(7475):1172. doi: 10.1136/bmj.329.7475.1172.

No abstract available.

Cite
Reidenberg MM, Walley T. The pros and cons of essential medicines for rich countries. BMJ. 2004;329(7475):1172doi: 10.1136/bmj.329.7475.1172.
Reidenberg, M. M., & Walley, T. (2004). The pros and cons of essential medicines for rich countries. BMJ (Clinical research ed.), 329(7475), 1172. https://doi.org/10.1136/bmj.329.7475.1172
Reidenberg, Marcus M, and Walley, Tom. "The pros and cons of essential medicines for rich countries." BMJ (Clinical research ed.) vol. 329,7475 (2004): 1172. doi: https://doi.org/10.1136/bmj.329.7475.1172
Reidenberg MM, Walley T. The pros and cons of essential medicines for rich countries. BMJ. 2004 Nov 13;329(7475):1172. doi: 10.1136/bmj.329.7475.1172. PMID: 15539677; PMCID: PMC527703.
Copy Download .nbib Format: NLM
Access to medicines, BRICS alliances, and collective action.

American journal of law & medicine

Yu PK.
PMID: 18697697
Am J Law Med. 2008;34(2):345-94. doi: 10.1177/009885880803400210.

No abstract available.

Cite
Yu PK. Access to medicines, BRICS alliances, and collective action. Am J Law Med. 2008;34(2):345-94doi: 10.1177/009885880803400210.
Yu, P. K. (2008). Access to medicines, BRICS alliances, and collective action. American journal of law & medicine, 34(2), 345-94. https://doi.org/10.1177/009885880803400210
Yu, Peter K. "Access to medicines, BRICS alliances, and collective action." American journal of law & medicine vol. 34,2 (2008): 345-94. doi: https://doi.org/10.1177/009885880803400210
Yu PK. Access to medicines, BRICS alliances, and collective action. Am J Law Med. 2008;34(2):345-94. doi: 10.1177/009885880803400210. PMID: 18697697.
Copy Download .nbib Format: NLM
Use of economic evaluation in decision making: evidence and recommendations for improvement.

Drugs

Simoens S.
PMID: 20883050
Drugs. 2010 Oct 22;70(15):1917-26. doi: 10.2165/11538120-000000000-00000.

Information about the value for money of a medicine as derived from an economic evaluation can be used for decision-making purposes by policy makers, healthcare payers, healthcare professionals and pharmaceutical companies. This article illustrates the use of economic evaluation...

Cite
Simoens S. Use of economic evaluation in decision making: evidence and recommendations for improvement. Drugs. 2010;70(15):1917-26doi: 10.2165/11538120-000000000-00000.
Simoens, S. (2010). Use of economic evaluation in decision making: evidence and recommendations for improvement. Drugs, 70(15), 1917-26. https://doi.org/10.2165/11538120-000000000-00000
Simoens, Steven. "Use of economic evaluation in decision making: evidence and recommendations for improvement." Drugs vol. 70,15 (2010): 1917-26. doi: https://doi.org/10.2165/11538120-000000000-00000
Simoens S. Use of economic evaluation in decision making: evidence and recommendations for improvement. Drugs. 2010 Oct 22;70(15):1917-26. doi: 10.2165/11538120-000000000-00000. PMID: 20883050.
Copy Download .nbib Format: NLM
Linking research to global health equity: the contribution of product development partnerships to access to medicines and research capacity building.

American journal of public health

Pratt B, Loff B.
PMID: 24028246
Am J Public Health. 2013 Nov;103(11):1968-78. doi: 10.2105/AJPH.2013.301341. Epub 2013 Sep 12.

Certain product development partnerships (PDPs) recognize that to promote the reduction of global health disparities they must create access to their products and strengthen research capacity in developing countries. We evaluated the contribution of 3 PDPs--Medicines for Malaria Venture,...

Cite
Pratt B, Loff B. Linking research to global health equity: the contribution of product development partnerships to access to medicines and research capacity building. Am J Public Health. 2013;103(11):1968-78doi: 10.2105/AJPH.2013.301341.
Pratt, B., & Loff, B. (2013). Linking research to global health equity: the contribution of product development partnerships to access to medicines and research capacity building. American journal of public health, 103(11), 1968-78. https://doi.org/10.2105/AJPH.2013.301341
Pratt, Bridget, and Loff, Bebe. "Linking research to global health equity: the contribution of product development partnerships to access to medicines and research capacity building." American journal of public health vol. 103,11 (2013): 1968-78. doi: https://doi.org/10.2105/AJPH.2013.301341
Pratt B, Loff B. Linking research to global health equity: the contribution of product development partnerships to access to medicines and research capacity building. Am J Public Health. 2013 Nov;103(11):1968-78. doi: 10.2105/AJPH.2013.301341. Epub 2013 Sep 12. PMID: 24028246; PMCID: PMC3828705.
Copy Download .nbib Format: NLM
The definition and role of quality of life in Germany's early assessment of drug benefit: a qualitative approach.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

Lohrberg D, Augustin M, Blome C.
PMID: 26242250
Qual Life Res. 2016 Feb;25(2):447-455. doi: 10.1007/s11136-015-1092-6. Epub 2015 Aug 05.

PURPOSE: In 2011, Germany introduced a new form of drug benefit assessment, linking reimbursement prices to drug benefit and making quality of life (QoL) one of the main benefit criteria. Thus, QoL outcomes co-determine drug prices in Germany. QoL...

Cite
Lohrberg D, Augustin M, Blome C. The definition and role of quality of life in Germany's early assessment of drug benefit: a qualitative approach. Qual Life Res. 2015;25(2):447-455doi: 10.1007/s11136-015-1092-6.
Lohrberg, D., Augustin, M., & Blome, C. (2016). The definition and role of quality of life in Germany's early assessment of drug benefit: a qualitative approach. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 25(2), 447-455. https://doi.org/10.1007/s11136-015-1092-6
Lohrberg, David, et al. "The definition and role of quality of life in Germany's early assessment of drug benefit: a qualitative approach." Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation vol. 25,2 (2016): 447-455. doi: https://doi.org/10.1007/s11136-015-1092-6
Lohrberg D, Augustin M, Blome C. The definition and role of quality of life in Germany's early assessment of drug benefit: a qualitative approach. Qual Life Res. 2016 Feb;25(2):447-455. doi: 10.1007/s11136-015-1092-6. Epub 2015 Aug 05. PMID: 26242250.
Copy Download .nbib Format: NLM
Multi-target drugs: the trend of drug research and development.

PloS one

Lu JJ, Pan W, Hu YJ, Wang YT.
PMID: 22768266
PLoS One. 2012;7(6):e40262. doi: 10.1371/journal.pone.0040262. Epub 2012 Jun 29.

Summarizing the status of drugs in the market and examining the trend of drug research and development is important in drug discovery. In this study, we compared the drug targets and the market sales of the new molecular entities...

Cite
Lu JJ, Pan W, Hu YJ, et al. Multi-target drugs: the trend of drug research and development. PLoS One. 2012;7(6):e40262doi: 10.1371/journal.pone.0040262.
Lu, J. J., Pan, W., Hu, Y. J., & Wang, Y. T. (2012). Multi-target drugs: the trend of drug research and development. PloS one, 7(6), e40262. https://doi.org/10.1371/journal.pone.0040262
Lu, Jin-Jian, et al. "Multi-target drugs: the trend of drug research and development." PloS one vol. 7,6 (2012): e40262. doi: https://doi.org/10.1371/journal.pone.0040262
Lu JJ, Pan W, Hu YJ, Wang YT. Multi-target drugs: the trend of drug research and development. PLoS One. 2012;7(6):e40262. doi: 10.1371/journal.pone.0040262. Epub 2012 Jun 29. PMID: 22768266; PMCID: PMC3386979.
Copy Download .nbib Format: NLM
Addressing the medicinal chemistry bottleneck: a lean approach to centralized purification.

ACS combinatorial science

Weller HN, Nirschl DS, Paulson JL, Hoffman SL, Bullock WH.
PMID: 22909004
ACS Comb Sci. 2012 Sep 10;14(9):520-6. doi: 10.1021/co300075g. Epub 2012 Aug 27.

The use of standardized lean manufacturing principles to improve drug discovery productivity is often thought to be at odds with fostering innovation. This manuscript describes how selective implementation of a lean optimized process, in this case centralized purification for...

Cite
Weller HN, Nirschl DS, Paulson JL, et al. Addressing the medicinal chemistry bottleneck: a lean approach to centralized purification. ACS Comb Sci. 2012;14(9):520-6doi: 10.1021/co300075g.
Weller, H. N., Nirschl, D. S., Paulson, J. L., Hoffman, S. L., & Bullock, W. H. (2012). Addressing the medicinal chemistry bottleneck: a lean approach to centralized purification. ACS combinatorial science, 14(9), 520-6. https://doi.org/10.1021/co300075g
Weller, Harold N, et al. "Addressing the medicinal chemistry bottleneck: a lean approach to centralized purification." ACS combinatorial science vol. 14,9 (2012): 520-6. doi: https://doi.org/10.1021/co300075g
Weller HN, Nirschl DS, Paulson JL, Hoffman SL, Bullock WH. Addressing the medicinal chemistry bottleneck: a lean approach to centralized purification. ACS Comb Sci. 2012 Sep 10;14(9):520-6. doi: 10.1021/co300075g. Epub 2012 Aug 27. PMID: 22909004.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 39 entries